Review of NICE Technology Appraisal Guidance No 121; Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma

 Proposal to defer the review

 The planned date for review of the above guidance was August 2010.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance.  However, we are aware of a number of ongoing trials which will conclude by the 2015. Consequently we propose that the review of the original guidance be deferred until 2015 to allow this research to be available to inform the review.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted.

August 2010